June 19, 2017
1 min read
Save
This article is more than 5 years old. Information may no longer be current.
Ocular Therapeutix reports $16 million quarterly loss
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Ocular Therapeutix reported a net loss of $16 million, or $0.58 per share, in the first quarter of 2017 compared with a net loss of $10.8 million, or $0.44 per share, in the first quarter of 2016, according to a company press release.
Total costs and operating expenses for the quarter totaled $16.1 million compared with $11 million in 2016’s first quarter, with research and development costs decreasing from $7.1 million in 2016’s first quarter to $6.7 million in 2017.
The first quarter of the year saw $0.5 million in revenue from sales of ReSure sealant.
Cash, cash equivalents and marketable securities equaled $80.4 million as of March 31.